The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Comparative Risk of Cardiovascular Events With Biologic and Synthetic Disease‐Modifying Antirheumatic Drugs in Patients With Rheumatoid Arthritis: A Systematic Review and Meta‐Analysis
Open accessAbstract
Objective: We performed a systematic review and meta‐analysis to evaluate the comparative effects of tumor necrosis factor inhibitors (TNF i), non‐TNF i biologics, and conventional synthetic disease‐modifying antirheumatic drugs (cs DMARD s) on cardiovascular risk in rheumatoid arthritis (RA). Methods: Using a systematic search through May 8, 2018, we included 14 observational studies in adults with RA treated with TNF i, non‐TNF i biologics, tofacitinib, or cs DMARD s, reporting the risk of major adverse cardiovascular events (MACE) or stroke. Only studies reporting active comparators were included. We performed random effects meta‐analysis and estimated odds ratios (OR s) and 95% confidence intervals (95% CI s). Results: As compared to TNF i, tocilizumab was associated with a decreased risk of MACE (OR 0.59 [95% CI 0.34–1.00]), whereas cs DMARD s were associated with an increased risk of MACE (cs DMARD s including methotrexate OR 1.45 [95% CI 1.09–1.93]; without methotrexate OR 2.57 [95% CI 1.32–5.00]), without heterogeneity (I 2 = 0%); there was no difference in risk of MACE between abatacept and TNF i (OR 0.89 [95% CI 0.71–1.11]), or between tocilizumab and abatacept (OR 0.81 [0.57–1.16]). Based on 11 cohorts (n = 135,053 patients), as compared to TNF i, cs DMARD s were associated with an increased risk of stroke (OR 1.17 [95% CI 1.01–1.36]); there was no difference in risk of stroke between different biologics (tocilizumab versus TNF i OR 0.98 [95% CI 0.59–1.61]; abatacept versus TNF i OR 1.08 [0.86–1.34]; tocilizumab versus abatacept OR 0.73 [95% CI 0.39–1.38]), without heterogeneity (I 2 = 0%). No comparative studies on cardiovascular risk with tofacitinib were identified. Conclusion: Based on meta‐analysis, as compared to TNF i, tocilizumab may be associated with a reduced risk of MACE, whereas cs DMARD s may be associated with an increased risk of MACE and stroke.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Assessing Bias in Studies of Prognostic Factors
Hayden, J. A., van der Windt, D. A., Cartwright, J. L., Côté, P., & Bombardier, C. (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-158-4-201302190-00009 · Cited by 3,287
How to read a funnel plot in a meta-analysis
Sedgwick, P., & Marston, L. (2015) · BMJ · doi:10.1136/bmj.h4718 · Cited by 318
Low, A. S. L., Symmons, D. P. M., Lunt, M., Mercer, L. K., Gale, C. P., Watson, K. D., Dixon, W. G., & Hyrich, K. L. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-209784 · Cited by 158
Cardiovascular Risk in Rheumatoid Arthritis: Comparing TNF-α Blockade with Nonbiologic DMARDs
Solomon, D. H., Curtis, J. R., Saag, K. G., Lii, J., Chen, L., Harrold, L. R., Herrinton, L. J., Graham, D. J., Kowal, M. K., Kuriya, B., et al. (2013) · The American Journal of Medicine · doi:10.1016/j.amjmed.2013.02.016 · Cited by 111
Self-citationBili, A., Tang, X., Pranesh, S., Bozaite, R., Morris, S. J., Antohe, J. L., Kirchner, H. L., & Wasko, M. C. M. (2014) · Arthritis Care & Research · doi:10.1002/acr.22166 · Cited by 75
Cited by
Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis
Ytterberg, S. R., Bhatt, D. L., Mikuls, T. R., Koch, G. G., Fleischmann, R., Rivas, J. L., Germino, R., Menon, S., Sun, Y., Wang, C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2109927 · Cited by 1,816
Metadata
- Authors
- Singh, S., Fumery, M., Singh, A. G., Singh, N., Prokop, L. J., Dulai, P. S., Sandborn, W. J., & Curtis, J. R.
- Venue
- Arthritis Care & Research
- Publisher
- Wiley
- Published
- 2020-03-27
- Volume
- 72
- Issue
- 4
- Pages
- 561-576
- ISSN
- 0893-7524 (ISSN-L)
- 2151-464X
- 2151-4658
- OpenAlex
- W2921889468
- Cited by
- 158
- References
- 5
- FWCI
- 5.02
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.